Adamis Pharmaceuticals Corporation Культура компании

Dr. Dennis J. Carlo, Ph.D. has been the Chief Executive Officer and President of Adamis Pharmaceuticals Corporation since April 2009. Dr. Carlo was a co-founder of Old Adamis and served as its President and Chief Executive Officer from October 2006 to April 2009. He served as the Chief Executive Officer and President of Cellegy Pharmaceuticals Inc. He co-founded Immune Response Corporation and also served as its President and Chief Executive Officer from September 1994 to September 2002 and Chief Scientific Officer from September 1998 to September 2002. He served as Immune Response Corporation's Chief Operating Officer from April 1987 to September 1994 and Executive Vice President from October 1987 to September 1994. Dr. Carlo served as an Assistant Corporate Secretary of Immune Response Corporation since 1987. From January 1982 to May 1987, Dr. Carlo served as Vice President of Research & Development and Vice President of Therapeutic Manufacturing at Hybritech Inc., a biotechnology company that was acquired by Eli Lilly & Company, a pharmaceutical company, in 1985. From 1971 to 1981, Dr. Carlo served in various positions at Merck & Co., Inc., including Director of Development & Basic Cellular Immunology and Director of Bacterial Vaccines & Immunology at Merck & Co., he oversaw research and product development for PNEUMOVAX (14-valent polysaccharide vaccine), MENINGOVAX A, MENINGOVAX C, MENINGOVAX A-C and H. influenza type b and also directed a multi-disciplinary task force whose goal was the development of novel adjuvants. He served as President of Telos Pharmaceuticals, a private biotechnology company, from 2003 to 2006. He has been a Director of Adamis Pharmaceuticals Corporation since April 2009. He serves as a Director of TransMolecular Inc., a privately-held biotech company. He served as Director of Cellegy Pharmaceuticals Inc. He served as a Director of Avanir Pharmaceuticals, Inc. from 1998 to September 2005. He served as a Director of Orchestra Therapeutics, Inc. ( formerly Immune Response Corp.) since 1987. He served as Director of Old Adamis from October 2006 to April 2009. He is named on 23 patents and has authored over 225 articles and abstracts in the field of Immunology. In 1991, Dr. Carlo received the Ernst & Young entrepreneur of the year award. He received a B.S. degree in microbiology from Ohio State University and has a Ph.D. in Immunology and Medical Microbiology from the Ohio State University. He holds Ms from the Ohio State University.

Mr. Robert B. Rothermel, also known as Bob, is a Partner of CroBern Management Partnership, which works exclusively within the health care industry. Mr. Rothermel serves as Consultant at Adamis Pharmaceuticals Corporation. He spent 37 years with Deloitte & Touche and served as a Partner and Global Managing Director of the Enterprise Risk Services practice. Mr. Rothermel lead client service partner for major corporations including Sears Roebuck & Co., American Hospital Supply Corporation and Molex Incorporated. He serves as Director of Medcor. Mr. Rothermel serves as Director of Pharmacy OneSource, Inc. He has been a Director of Adamis Pharmaceuticals Corporation since August 2014. He served as the Director of CEREHEALTH CORP. since November 2009. He serves as a Director of three CroBern portfolio companies. He served as Director of Adamis Pharmaceuticals Corp. from January 2004 to June 19, 2009. Mr. Rothermel served as Director of Cellegy Pharmaceuticals Inc. since January 21, 2004. He served as Director of Adamis Pharmaceuticals Corporation since January 2004 until June 19, 2009. He also served as a member of Deloitte & Touche's Board of Directors. Mr. Rothermel has a Bachelor of Science degree in Business Administration from Bowling Green State University.

Mr. David J. Marguglio has been a Senior Vice President and Chief Business Officer at Adamis Pharmaceuticals Corporation since March 2017. Mr. Marguglio served as a Senior Vice President of Corporate Development at Adamis Pharmaceuticals Corporation. Mr. Marguglio joined Adamis Pharmaceuticals Corporation as Vice President of Business Development and Investor Relations in April 2009 in connection with the closing of the merger transaction between Cellegy and Old Adamis. Mr. Marguglio was a co-founder of Old Adamis and served as its Vice President of Business Development and Investor Relations since its inception in June 2006 until April 2009. He served as a Vice President of Business Development & Investor Relations at Cellegy Pharmaceuticals Inc. since June 2006. From 1996 to 2006, he held various positions of Vice President with Citigroup Global Markets, Smith Barney and Merrill Lynch. Before entering the financial industry, from 1994 to 1996, he founded and ran two different startup companies, the latter of which was eventually acquired by a Fortune 100 company. From 1993 to 1994, he served as financial counsel for the commercial litigation division of a national law firm. Mr. Marguglio began his career as a financial analyst. He has been a Director of Adamis Pharmaceuticals Corporation since April 2009. He served as Director of Cellegy Pharmaceuticals Inc. since April 2009. He received a degree in finance and Business Management from the Hankamer School of Business at Baylor University.

Mr. Robert O. Hopkins has been the Chief Financial Officer and Vice President of Finance of Adamis Pharmaceuticals Corporation since April 2009 and serves as its Secretary. Mr. Hopkins served as Chief Financial Officer and Vice President of Finance at Old Adamis since April 2007 until April 2009. He served as the Chief Financial Officer and Secretary of Cellegy Pharmaceuticals Inc. since April 2007. From 2000 to 2004, he served as an Executive Vice President and the Chief Financial Officer of Chatham Capital Corp. Mr. Hopkins served as the Chief Financial Officer of Veritel Corp. from 1999 to 2000, a biometric software company. He also served as the Chief Operating Officer of Circle Trust Company from 2004 to 2005, during which time he was responsible for corporate reorganization after acquiring a troubled trust company. From 2005 to April 2007, he consulted for Acumen Enterprises providing analysis and business plans for the various projects with which it was involved. From 1997 to 1999, Mr. Hopkins served as Senior Vice President, Finance of the Mariner Post-Acute Network, Atlanta, Georgia. Among his previous medical-related experience, he served as Assistant Administrator of Finance at Kindred Hospitals; President and Chief Executive Officer of Doctors Hospital of Hyde Park; and Vice President of Accounting for Cancer Treatment Centers of America. He received a B.S. degree in Finance from the Indiana State University and an M.B.A. from Lake Forest Graduate School of Management.

Dr. Ronald B. Moss, also known as Ron, M.D. has been Chief Medical Officer at Adamis Pharmaceuticals Corporation since February 2017. Dr. Moss served as President and Chief Executive Officer at Ansun Biopharma, Inc. (formerly, NexBio)from October 2012 to February 2017 and as interim Chief Executive Officer from October 2011 to October 2012. and served as its Executive Vice President of Clinical Development & Medical Affairs. Dr. Moss served as the President of Orchestra Therapeutics, Inc. from September 2002 to January 2003. Dr. Moss served as Vice President of Clinical Development of Vical Inc., since June 5, 2006 until January 2009. He served as a Vice-President of Medical Affairs at Telos Pharmaceuticals from January 2004 to March 2006. Dr. Moss joined The Immune Response Corp. in January, 1994 as Medical Director and advanced through positions of increasing responsibility and served as the Interim President and Chief Executive Officer from August 2002 to January 2003. From 2003 to 2004, he served as a Senior Director of Worldwide Regulatory Affairs for Vaccines/Biologics in the Merck Research Laboratories Division of Merck and Co., Inc., from January 2003 to January 2004, where he worked on multiple vaccine programs. He served as Assistant Medical Director at Immunization Products Ltd., from July 1993 to January 1994 a joint venture between Rhone-Poulenc Rorer and Immune Response. Dr. Moss trained first as a Pediatrics Resident at SUNY and then as a Clinical Associate in Allergy and Clinical Immunology at the National Institutes of Health and is board certified in pediatrics and in allergy & immunology. Dr. Moss served as the Chairman of the Scientific Advisory Board for VG Life Sciences Inc. and served as its Member of Scientific and Medical Advisory Board. He has Authored or Co-authored more than 60 scientific papers, is an inventor on five patents and has been inducted into the prestigious Alpha Omega Alpha Medical Honor Society. He is a Fellow of the American Academy of Allergy Asthma and Immunology (FAAAI) and a Fellow of the American College of Allergy, Asthma and Immunology (FCAAI). Dr. Moss is a voluntary faculty member at University of California, San Diego, School of Medicine Department of Medicine. He earned his M.D. degree in 1987 at the Chicago Medical School, Rosalind Franklin University of Medicine and Science and graduated Phi Beta Kappa with a bachelor's degree in 1982 from the State University of New York at Stony Brook.

Ms. Karen K. Daniels has been a Vice President of Operations at Adamis Pharmaceuticals Corporation since July 2009. Ms. Daniels has over 30 years of experience in operational and engineering roles across diverse industries including electronics, medical devices, contract manufacturing and pharmaceutical manufacturing. She served as General Manager for Plexus Corporation and Chief Operating Officer of Qtron which was sold to Plexus from 1999 to 2003. She also served as Senior Director of Operations and Logistics for Vidacare, a medical device manufacturer from 2006 to 2007. From 2003 to 2006, she was President of Lambda Power. She served as President at Bio-services Division of Ajinomoto Althea, Inc. (formerly, Althea Technologies Inc.) from July 17, 2007 to 2009. Ms. Daniels holds a Bachelors of Science degree from the University of Arizona with a strong background in Biology and Engineering.

Mr. Eddie Wabern Glover co-founded US Compounding, Inc. (USC) in 2005 and has been President and Chief Executive Officer since 2005. Mr. Glover serves as Director at International Academy of Compounding Pharmacists. Mr. Glover serves as president of the Arkansas Pharmacist Association. Mr. Glover is a member of the National Community Pharmacists Association (NCPA) and Professional Compounding Centers Of America (PCCA). Mr. Glover served on the board of directors of the Arkansas Pharmacy Association, Pharmacy Partners of America and the International Association of Compounding Pharmacist. He was named NCPA 'Pharmacist of the Year' in 2012 and PCCA 'Pharmacist of the Year' in 2009. Mr. Glover is a graduate of the University of Central Arkansas and received his Pharmacy degree from the University of Oklahoma.

Charles Lollo serves as the Executive Director of Adamis Pharmaceuticals Corporation. Charles started at Adamis Pharmaceuticals Corporation in Apr of 2018. Charles currently resides in the Greater San Diego Area.

Gus Fernandez serves as the Vice President, Commercial Operations of Adamis Pharmaceuticals Corporation. Gus started at Adamis Pharmaceuticals Corporation in March of 2015. Gus currently resides in the Greater San Diego Area.

Ronald Moss serves as the Chief Medical Officer of Adamis Pharmaceuticals Corporation. Ronald started at Adamis Pharmaceuticals Corporation in February of 2017. Ronald currently resides in the Greater San Diego Area.